MarketPulse
N

$NVO

64 articles found
24 positive
16 negative
23 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Turner Syndrome Treatment Market Set to Double by 2033 on Diagnostic Innovation

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.
PFELLYNVSSNYNVO+2healthcarerare disease
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.3% Yield Hinges on GLP-1 Drug Data, Patent Cliff Challenges

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.
PFELLYNVOdividend yieldclinical trial results
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition